Cannabis decriminalisation in Europe

TL;DR

• Portugal 2001: comprehensive decriminalisation of all drugs — drop in new HIV infections.
• Netherlands 1976: coffeeshop model under the Opiumwet.
• Malta 2021: first EU country to allow home cultivation.
• Germany 1 April 2024: cannabis law (home-grow + cannabis clubs).

What does the evidence show?

After 20 years of the Portuguese model (Hughes & Stevens 2010; SICAD reports), consumption is stable, drug deaths and new HIV infections have fallen sharply. Germany launched on 1 April 2024 with home-grow (max 3 plants) and non-commercial cannabis clubs; commercial sale remains prohibited.

The Swiss approach in European comparison

While European states such as Germany or Malta rely on a partial decriminalisation of home cultivation, Switzerland is pursuing a scientifically monitored special path. With the legal anchoring of pilot trials in the Narcotics Act, the Confederation enables the regulated sale of cannabis containing THC in selected cities. These time-limited projects, including initiatives in Zurich and Basel, serve to research consumption habits and social impacts under state control. At the same time, consumption outside of these studies and without a medical indication remains a minor offence that can be punished in a simplified procedure.

A striking difference to neighbouring European countries is also evident in the limit values. In Switzerland, cannabis with a total THC content of less than one percent is not considered a narcotic and is therefore legally available on the market. This regulation, which is generous compared to other European countries, has created a flourishing market for CBD products. In road traffic, on the other hand, there is a strict zero-tolerance policy with an extremely low detection limit in the blood. Anyone who exceeds the permitted limits must expect harsh criminal consequences and the revocation of their driving licence.

• Scientific pilot trials to test regulated points of sale in Swiss cities.
• Liberal limit of less than one percent total THC for legal purchase and consumption.
• Strict zero-tolerance practice in road traffic with a limit of 1.5 micrograms of THC per litre of blood.
• Fixed penalty procedures for minor possession of THC cannabis outside of the pilot projects for adults.

Regulatory models and the grey area of decriminalisation

The European landscape of cannabis reforms is characterised by conceptual nuances that translate into significant differences in practice. At its core, decriminalisation means that the acquisition and possession of small quantities for personal use are no longer prosecuted as criminal offences, but are instead classified as administrative offences. This differs fundamentally from full legalisation, where the entire supply chain from cultivation to sale is state-regulated and licensed. Many European countries remain in a grey area where consumption is tolerated, but procurement is still left to the illegal market.

This discrepancy often leads to systemic problems, as consumers remain dependent on unregulated sources despite decriminalisation. Without state quality control, the risk of contamination and unpredictable concentrations of active ingredients remains high. Some regions attempt to bridge this gap through the model of collective cultivation associations, where members are permitted to grow cannabis for personal use. Nevertheless, practice shows that mere decriminalisation of consumption without market regulation can only weaken organised crime to a limited extent and often leaves questions of the protection of minors unresolved.

• Distinction between penalty-free consumption (decriminalisation) and a state-regulated market (legalisation).
• Persistence of the black market in the absence of regulation of production and distribution.
• Risks due to a lack of quality controls and unclear active ingredient levels in unregulated purchases.
• Models such as cultivation associations as an intermediate step towards harm reduction without commercial sales.

Social and health policy implications

The realignment of cannabis policy in Europe reflects a paradigm shift from law enforcement to harm reduction. Decriminalisation destigmatises consumers, which significantly facilitates access to state support and counselling services. Instead of investing resources in prosecuting low-level consumers, the justice system and police can be relieved, and financial resources can be targeted towards prevention and addiction support. Accompanying scientific studies show that the fear of an explosive rise in consumer numbers following decriminalisation has not materialised in most countries.

Nevertheless, the health policy support poses major challenges for the authorities. In particular, the protection of minors requires specific measures, as consumption during adolescence is associated with particular risks to brain development. European countries implementing reforms are therefore increasingly relying on educational campaigns and the expansion of early detection systems. The evidence suggests that controlled distribution or clear decriminalisation, combined with strong prevention work, can reduce public health risks more effectively than outright bans.

• Relief for law enforcement authorities and the judiciary through the elimination of minor offence proceedings.
• Improved access to prevention and therapy services by reducing social stigmatisation.
• Focus on the protection of minors through targeted educational campaigns and age checks in pilot projects.
• Scientific findings point to stable consumption rates while simultaneously increasing consumption safety.

FAQ